Barcelo et al. (20) conducted a study to determine the direct costs (healthcare expenses such as insulin, oral hypoglycemic agents, tests, consultations, hospitalizations, emergency visits, and complications treatment) and indirect costs (lost resources due to premature mortality and temporary and permanent disabilities) related to diabetes in 29 countries from Latin America and the Caribbean in 2015 (20). The gene discussed is INS; the disease is diabetes mellitus.